EUCTR2019-003162-41-DE进行中（未招募）1 期
An investigator-initiated, multi-center, randomized, double-blind, placebo controlled study of Dupilumab to demonstrate efficacy in subjects with nummular eczema
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Clinically confirmed diagnosis of NE
- •2.Biopsy-proven, meaning histology consistent with eczema (including PAS-staining)
- •3.EASI score = 10
- •4.History of continuous use of topical steroids for the last 8 weeks
- •5.Age 18-85 years of age, body weight = 40 kg and = 160 kg
- •6.Female participants who are not capable of bearing children or who use a method of contraception that is medically approved by the health authority of the respective country at screening.
- •7.History of continuous use of at least mid-potency topical steroids for the last 8 weeks.
- •8.Age 18-85 years of age, body weight = 40 kg and = 160 kg.
- •9.Signed informed consent from patient.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 50
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 20
排除标准
- •1)Permanent severe diseases, especially those affecting the immune system.
- •2)Pregnancy or breast feeding.
- •3)Active chronic or acute infection requiring systemic treatment within 2 weeks before the baseline visit, independent from of the cuntaneous dysbiosis found in NE.
- •4)Treatment with an investigational drug within 8 weeks before the baseline visit*.
- •5)Treatment with a live (attenuated) vaccine within 12 weeks before the baseline visit.
- •6)Diagnosed active endoparasitic infections or at high risk of these infections.
- •7)Evidence of severe renal dysfunction defined as:
- •- eGFR < 30 ml/min/1,73 m2 (calculated using the cockroft gold formula) at screening (Visit 1)
- •8)Evidence of significant hepatic disease defined as:
- •At screening (Visit 1):
- •- Alkaline phosphatase >3x upper limit of normal (ULN) or alkaline phosphatase >2,5x ULN and total bilirubin > 2xULN
- •- Aspartate transaminase (AST, SGOT]) and alanine transaminase (ALT, SGPT]) > 2.5x upper limit of normal (ULN).
- •9)Patients who are considered potentially unreliable or where it is envisaged the patient may not consistently attend scheduled study visits.
- •10)Inability or unwillingness to undergo repeated venipuncture (e.g., because of poor tolerability or lack of access to veins).
- •11)Inability or unwillingness to undergo repeated punch biopsies.
- •12)History of allergy to any component of the study medication.
- •13)Evidence of acute contact dermatitis at screening.
- •14)Evidence of Zink deficiency defined as Zink level < 20 µg/dL in serum.
- •15) History of important side effects of medium potency topical corticosteroids (eg, intolerance to treatment, hypersensitivity reactions*, significant skin atrophy, systemic effects), as assessed by the investigator or patient’s treating physician.
- •16.) =30% of the total lesional surface located on areas of thin skin that cannot be safely treated with medium potency TCS (eg, face, neck, intertriginous areas, genital areas, areas of skin atrophy) at baseline.
- •17.) Planned or anticipated use of any prohibited medications and procedures during study treatment.
- •18.) Known history of human immunodeficiency virus (HIV) infection.
- •19.) Established diagnosis of Hepatitis B viral infection at the time of screening.
- •20.) Established diagnosis of hepatitis C viral infection at the time of screening.
- •21.) History of past or current tuberculosis or other mycobacterial infection.
- •22.) Presence of skin comorbidities that may interfere with study assessments. This includes, but is not limited to, conditions like scabies, seborrheic dermatitis, Cutaneous T cell Lymphoma, Psoriasis, etc.
- •23.) Malignancy within 5 years of the screening visit excluding local cutaneous squamous cell
- •24.) Severe concomitant illness(es) that, in the investigator's judgment, would adversely affect the patient's participation in the study. Examples include, but are not limited to patients with short life expectancy, patients with major congenital malformations, patients with cardiovascular conditions (eg, major, clinically significant congenital cardiovascular abnormalities), severe renal conditions, hepato-biliary conditions (eg, Child-Pugh class B or C), active major autoimmune diseases (eg, lupus, inflammatory bowel disease etc.), other severe endocrinological, gastrointestinal, metabolic, pulmonary, neurological or lymphatic diseases. The specific justification for patients excluded under this criterion will be noted in study documents (chart notes, case report forms [
研究者
相似试验
招募中
不适用
Comparison of hemostatic agent to suture in terms of hemostatic function and preservation of ovarian functioDiseases of The genitoruinary systemKCT0005586Seoul National University Hospital90
终止
4 期
Pilot phase for the Tension-type HeadAche Prevention Project (HAPPy Too) to investigate in a double-blind, randomised trial whether treatment with low-dose blood pressure (BP) lowering therapy on top of standard care will reduce tension-type headache compared to placebo and standard care.Tension-type HeadacheACTRN12617001323314The George Institute for Global Health120
终止
4 期
Pilot phase for the workplace migraine HeadAche Prevention Project (HAPPy - pilot) to investigate in a double blind randomised factorial trial whether treatment with low-dose combination blood pressure (BP) and cholesterol lowering therapy will reduce migraine compared to standard therapy and placebo.Other - Conditions of unknown or disputed aetiology (such as chronic fatigue syndrome/myalgic encephalomyelitis)MigraineACTRN12616000937415The George Institute for Global Health180
进行中（未招募）
1 期
Efficacy, safety, tolerability, and pharmacokinetics of MIJ821 inpatients with treatment-resistant depressioEUCTR2018-003002-12-ESovartis Farmacéutica, S.A.70
进行中（未招募）
1 期
lcerative colitisMild to moderate ulcerative colitisMedDRA version: 20.0Level: PTClassification code 10009900Term: Colitis ulcerativeSystem Organ Class: 10017947 - Gastrointestinal disordersMedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2019-003113-34-DEovartis Pharma AG45